DDInter1770 DDInter596
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Terfenadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Terfenadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Terfenadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lasmiditan
Lasmiditan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxorubicin (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Doxorubicin (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)